# NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

> **NCT05664217** · PHASE2,PHASE3 · TERMINATED · sponsor: **Nektar Therapeutics** · enrollment: 15 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** NKTR-255 at 1.5 µg/kg
- **DRUG:** NKTR-255 at 3.0 μg/kg
- **DRUG:** NKTR-255 at 3.0/6.0 μg/kg
- **OTHER:** Placebo Comparator

## Key facts

- **NCT ID:** NCT05664217
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-23
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-08-16
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor decided to end the study
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05664217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05664217, "NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05664217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*